Back to News
Market Impact: 0.4
Lilly's EBGLYSS Shows Rapid Skin Clearance And Symptom Relief In Phase 3b Study
Source: Nasdaq
Healthcare & BiotechCompany Fundamentals
Eli Lilly said EBGLYSS (lebrikizumab-lbkz) met primary and secondary endpoints in the Phase 3b ADtouch trial for moderate-to-severe hand and foot atopic dermatitis. The study showed significant improvements in skin clearance, itch and pain among adult and adolescent patients, supporting the treatment's clinical profile and potential commercial expansion.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
moderately positive
Sentiment Score
0.58
Ticker Sentiment
LLY0.82
More News
- Eli Lilly says closely watched combo obesity regimen boosts weight loss in mid-stage trial
- Lilly’s Foundayo shows cardiovascular safety in diabetes trial
- Nvidia is approaching a breakout level. Plus, what we want to see from Micron
- Wall Street is closing out a strong quarter. Plus, Lilly's mixed obesity drug trial data
- Adding Lilly’s new drug to Zepbound helped people lose up to 23% of their weight. But there were more side effects.
- Lilly's oral GLP-1, Foundayo (orforglipron), demonstrated cardiovascular safety alongside sustained A1C reduction and weight loss in its largest and longest type 2 diabetes study
From AllMind Research
- Anthropic IPO Preview: Valuation, Timing, and What to Watch
- Shein After the IPO: Venue, Valuation, and What Must Be Proved
- What AI Research Tools Should a Small Hedge Fund Buy First?
- Palantir (PLTR) Q4 2025 Earnings: 70% Revenue Growth, Then an 11% Single-Day Crash
- AlphaSense Pricing: What Public Contract Data Shows in 2026